GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
| Mar2021 | ₹14,069 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | 9.44 | |
| Mar2021 | ₹14,069 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹64,120.1 Cr | -1.2% | -1.5% | 11.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹464,271.0 Cr | -0.5% | -0.3% | 18.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹226,843.0 Cr | 3.1% | 18.9% | 33.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,000.0 Cr | -1.5% | -1.6% | 35.6% | Stock Analytics | |
| CIPLA | ₹118,072.0 Cr | -0.9% | 1.6% | -2.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,073.0 Cr | 2% | -3.8% | -0.7% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -1.2% |
-1.5% |
11.6% |
| SENSEX | -0.8% |
0.5% |
-3.8% |
You may also like the below Video Courses